CATX icon

Perspective Therapeutics

2.05 USD
+0.09
4.59%
At close Apr 2, 4:00 PM EDT
After hours
2.02
-0.03
1.46%
1 day
4.59%
5 days
-8.48%
1 month
-16.67%
3 months
-38.07%
6 months
-84.48%
Year to date
-38.07%
1 year
-85.96%
5 years
-61.17%
10 years
-86.51%
 

About: Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Employees: 140

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

58% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 31

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

6% more funds holding

Funds holding: 127 [Q3] → 134 (+7) [Q4]

2.96% less ownership

Funds ownership: 72.86% [Q3] → 69.9% (-2.96%) [Q4]

37% less call options, than puts

Call options by funds: $331K | Put options by funds: $527K

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

77% less capital invested

Capital invested by funds: $655M [Q3] → $151M (-$505M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
388%
upside
Avg. target
$12.75
522%
upside
High target
$15
632%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
15% 1-year accuracy
26 / 171 met price target
388%upside
$10
Buy
Reiterated
31 Mar 2025
RBC Capital
Gregory Renza
0 / 0 met price target
632%upside
$15
Outperform
Maintained
27 Mar 2025
Wedbush
David Nierengarten
34% 1-year accuracy
39 / 116 met price target
437%upside
$11
Outperform
Reiterated
27 Mar 2025
Scotiabank
Louise Chen
32% 1-year accuracy
43 / 133 met price target
632%upside
$15
Sector Outperform
Initiated
7 Mar 2025

Financial journalist opinion

Based on 5 articles about CATX published over the past 30 days

Positive
Zacks Investment Research
9 hours ago
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Neutral
GlobeNewsWire
2 days ago
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
Neutral
GlobeNewsWire
1 week ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2024.
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
Neutral
GlobeNewsWire
2 weeks ago
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Positive
Benzinga
2 weeks ago
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. CATX, a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment.
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
Neutral
GlobeNewsWire
1 month ago
Perspective Therapeutics to Present at Upcoming March Investor Conferences
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Perspective Therapeutics to Present at Upcoming March Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Cohorts 1 and 2 who previously experienced stable disease remain in stable disease SEATTLE, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) taking place January 23-25, 2025 in San Francisco, CA.
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Neutral
GlobeNewsWire
2 months ago
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO).
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
Charts implemented using Lightweight Charts™